Drugs / LT-002-158
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06082323 | Jun 2024 → Mar 2025 overdue | atopic eczema, hidradenitis suppurativa | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06932003 | Apr → Oct 2025 overdue | hidradenitis suppurativa | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06931990 | Apr → Oct 2025 overdue | atopic eczema | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LT-002-158 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06931990 ↗ |
| Modality | Other / unclassified | “IRAK4 protein degrader” NCT06082323 ↗ |
| Route | Oral | “orally administered LT-002-158” NCT06082323 ↗ |
| Target | IRAK4 | “IRAK4 protein degrader” NCT06082323 ↗ |